LIFECORE BIOMEDICAL INC (LFCR)
US5147661046 - Common Stock
LFCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 59 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of LFCR have multiple concerns. LFCR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
LFCR had negative earnings in the past year.
In the past year LFCR has reported a negative cash flow from operations.
LFCR had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: LFCR reported negative operating cash flow in multiple years.
1.2 Ratios
LFCR has a worse Return On Assets (-39.24%) than 88.14% of its industry peers.
Looking at the Return On Equity, with a value of -267.71%, LFCR is doing worse than 93.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.24% | ||
| ROE | -267.71% | ||
| ROIC | N/A |
ROA(3y)-29.28%
ROA(5y)-18.96%
ROE(3y)-138.6%
ROE(5y)-86.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 25.60%, LFCR is not doing good in the industry: 84.75% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of LFCR has grown nicely.
The Profit Margin and Operating Margin are not available for LFCR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 25.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.4%
GM growth 5Y12.09%
2. Health
2.1 Basic Checks
LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFCR has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, LFCR has more shares outstanding
Compared to 1 year ago, LFCR has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.02, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.02, LFCR is not doing good in the industry: 72.88% of the companies in the same industry are doing better.
LFCR has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
LFCR's Debt to Equity ratio of 2.71 is on the low side compared to the rest of the industry. LFCR is outperformed by 91.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.02 |
ROIC/WACCN/A
WACC11.32%
2.3 Liquidity
LFCR has a Current Ratio of 2.56. This indicates that LFCR is financially healthy and has no problem in meeting its short term obligations.
LFCR has a Current ratio of 2.56. This is comparable to the rest of the industry: LFCR outperforms 47.46% of its industry peers.
A Quick Ratio of 1.39 indicates that LFCR should not have too much problems paying its short term obligations.
The Quick ratio of LFCR (1.39) is worse than 71.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.56 | ||
| Quick Ratio | 1.39 |
3. Growth
3.1 Past
LFCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -518.52%.
The Revenue for LFCR has decreased by -20.59% in the past year. This is quite bad
LFCR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.74% yearly.
EPS 1Y (TTM)-518.52%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-8800%
Revenue 1Y (TTM)-20.59%
Revenue growth 3Y-13.6%
Revenue growth 5Y-27.74%
Revenue growth Q2Q-33.73%
3.2 Future
Based on estimates for the next years, LFCR will show a very strong growth in Earnings Per Share. The EPS will grow by 27.14% on average per year.
Based on estimates for the next years, LFCR will show a small growth in Revenue. The Revenue will grow by 5.14% on average per year.
EPS Next Y74.35%
EPS Next 2Y38.37%
EPS Next 3Y27.14%
EPS Next 5YN/A
Revenue Next Year-9.64%
Revenue Next 2Y2.11%
Revenue Next 3Y5.14%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LFCR. In the last year negative earnings were reported.
Also next year LFCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LFCR's earnings are expected to grow with 27.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.37%
EPS Next 3Y27.14%
5. Dividend
5.1 Amount
No dividends for LFCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIFECORE BIOMEDICAL INC
NASDAQ:LFCR (4/19/2024, 7:01:08 PM)
After market: 6.69 0 (0%)6.69
+0.38 (+5.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap204.38M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.24% | ||
| ROE | -267.71% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 25.6% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.56 | ||
| Quick Ratio | 1.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-518.52%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y74.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.59%
Revenue growth 3Y-13.6%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y